Fennec Pharmaceuticals Inc. (TSE:FRX) Director Sells C$87,552.00 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 10,000 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of C$8.76, for a total transaction of C$87,552.00.

Rostislav Christov Raykov also recently made the following trade(s):

• On Friday, December 20th, Rostislav Christov Raykov acquired 25,000 shares of Fennec Pharmaceuticals stock. The stock was purchased at an average cost of C$3.87 per share, with a total value of C$96,840.00.
• On Thursday, December 5th, Rostislav Christov Raykov bought 796 shares of Fennec Pharmaceuticals stock. The stock was purchased at an average cost of C$8.52 per share, for a total transaction of C$6,779.05.

Fennec Pharmaceuticals Stock Down 2.1 %

FRX opened at C$8.59 on Friday. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68. The stock’s fifty day simple moving average is C$7.86 and its 200 day simple moving average is C$7.64. Fennec Pharmaceuticals Inc. has a 1-year low of C$5.65 and a 1-year high of C$15.20. The stock has a market cap of C$235.02 million, a PE ratio of 85.90 and a beta of 0.25.

Analysts Set New Price Targets

Separately, Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.